FRESENIUS KABI USA LLC

FRESENIUS KABI USA LLC filed a Q1 report for FRESENIUS KABI USA LLC on April 20, 2026.

All filings by FRESENIUS KABI USA LLC · Everything FRESENIUS KABI USA LLC has reported

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Jun 18, 2026.

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$1,070,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Illinois

Official filing document

Government bodies contacted 13

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Trade (domestic/foreign)

Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)

Medicare/Medicaid

CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency

Health Issues

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement

Manufacturing

Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)

PTAB Proposed Rule - Restrict Use of IPR Patent Legislation Ancillary Product Patent Reform Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining

Taxation/Internal Revenue Code

Tax Incentives for Domestic Manufacturing Tax Credits for Domestic Manufacturing of Essential Medicines

Bills named in this filing 3

S. 2276
ETHIC Act
H.R. 3269
ETHIC Act
S. 2296
National Defense Authorization Act for Fiscal Year 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.